Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.
Artivion, Inc. Chief Commercial Officer John E. Davis reported two equity transactions in company common stock. On March 2, 2026, he acquired 28,845 shares at $0.00 per share, issued upon vesting of performance stock units from a February 2025 grant. On March 3, 2026, 4,573 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. Following these movements, Davis held 230,794 shares of Artivion common stock directly.
Artivion, Inc. executive Lance A. Berry reported equity compensation activity and a related tax sale of shares. He acquired 40,874 shares of common stock on a grant or award basis at a price of $0.0000 per share on March 2, 2026, connected to performance stock units granted on February 28, 2025. One third of these units were issued on March 2, 2026, with the remaining thirds scheduled to be eligible to vest on February 28, 2027 and February 28, 2028, assuming continued employment.
On March 3, 2026, 6,316 shares of common stock were sold in an open-market transaction at an average price of $37.7756 per share to cover tax withholding obligations arising from the vesting of these performance stock units. The filing states this “sell to cover” transaction was undertaken to satisfy tax obligations and does not represent a discretionary trade. Following these transactions, Berry directly held 210,827 shares of Artivion common stock.
Artivion, Inc. President & CEO James P. Mackin reported both an equity award and a related share sale. He acquired 116,948 shares of common stock on a grant/award basis at $0.00 per share following the vesting of performance stock units from a February 2025 grant.
On the next trading day, he sold 17,887 shares of common stock at an average price of $37.7756 per share in an open‑market transaction specifically to cover tax withholding obligations under a “sell to cover” arrangement, characterized as a non‑discretionary transaction. Following these transactions, he directly owned 947,275 shares of Artivion common stock.
Jean F Holloway reports proposed sales of common stock under Rule 144. The notice lists recent transactions including 03/02/2026 sale of 2,183 shares for $83,008.36, 02/24/2026 sale of 1,668 shares for $59,535.92, and 02/23/2026 sale of 3,079 shares for $115,733.45.
AORT: Section 144 notice reporting restricted stock vesting and recent insider sales.
The filing lists 6,316 common shares associated with a restricted stock vesting event on 02/27/2026. It also discloses three sales by Lance Berry: 4,981 shares (proceeds $187,223.34) on 02/23/2026, 4,885 shares (proceeds $160,082.66) on 02/24/2026, and 5,178 shares (proceeds $196,892.93) on 03/02/2026.
John E. Davis reported insider share transactions under Form 144 relating to AORT common stock. The filing lists proposed restricted-stock vesting of 4,573 shares on 02/27/2026 and discloses sales executed in the prior three months: 3,773 shares on 02/23/2026 ($141,817.64), 2,075 shares on 02/24/2026 ($74,062.77), and 2,784 shares on 03/02/2026 ($105,861.32).
AORT reported proposed insider sales of Common Stock under Form 144 by Jean F. Holloway. The filing lists sales on 02/23/2026 of 3,079 shares for $115,731.92, on 02/24/2026 of 1,668 shares for $59,535.76, and on 03/02/2026 of 2,183 shares for $83,008.36. The broker listed is Fidelity Brokerage Services LLC with an execution reference date of 03/03/2026.
AORT reported proposed sales of common stock via Form 144 by an affiliated holder. The notice lists proposed dispositions of 2,423, 1,259, and 1,513 shares on 02/23/2026, 02/24/2026, and 03/02/2026, respectively, with corresponding proceeds shown. The filing also shows 2,149 restricted shares vested on 02/27/2026.
AORT filed a Form 144 notifying the proposed sale of 17,887 shares of common stock dated 02/27/2026 associated with restricted stock vesting.
The filing also reports prior sales by James Mackin: 30,921 shares on 12/03/2025, 20,962 shares on 02/23/2026, 13,936 shares on 02/24/2026, and 14,911 shares on 03/02/2026, with each sale accompanied by the reported sale proceeds in the excerpt.